Canada markets open in 9 hours 18 minutes

Entheon Biomedical Corp. (ENTBF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0264+0.0040 (+17.84%)
At close: 01:04PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.0224
Open0.0279
BidN/A x N/A
AskN/A x N/A
Day's Range0.0250 - 0.0279
52 Week Range0.0140 - 0.4320
Volume24,771
Avg. Volume20,483
Market Cap1.696M
Beta (5Y Monthly)0.23
PE Ratio (TTM)N/A
EPS (TTM)-0.1060
Earnings DateOct 28, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Entheon Announces Closing of Previously Announced Sale of Certain DMT Clinical Assets

    Vancouver, British Columbia--(Newsfile Corp. - July 11, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") today announced that, further to its news release dated June 7, 2022, it has completed the sale of its Phase 1 N,N-dimethyltryptamine ("DMT") study (the "DMT Study") to Cybin IRL Limited (the "Purchaser"), a subsidiary of Cybin Inc. pursuant to an asset purchase agreement for a purchase price of CAD$1,000,000 (the "Transaction"). ...

  • Newsfile

    Entheon Announces Sale of Certain DMT Clinical Assets and Filing of Provisional Novel Compound Patents

    Vancouver, British Columbia--(Newsfile Corp. - June 7, 2022) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company") today announced that it has entered into a definitive agreement (the "Agreement") dated June 7, 2022 with Cybin IRL Limited (the "Purchaser"), a subsidiary of Cybin Inc. ("Cybin"), pursuant to which the Company has agreed to sell its Phase 1 N,N-dimethyltryptamine ("DMT") study (the "DMT Study") to the Purchaser (the "Transaction") for ...

  • GlobeNewswire

    Ehave, Inc. Announces Psychedelics Precision Medicine Platform For Clinical Research

    AI-driven discovery platform enables new way to find novel pathways, as well as progress towards identifying patients who may better respond to drugs in the clinicGenetic test kit evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted therapy MIAMI, June 01, 2022 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a leading healthcare services and technology company, announced today its KetaDASH subsidiary will begin using precision med